Target intelligence / Profile preview

Large-conductance calcium-activated potassium channel (KCNMA1 alpha subunit) (BK channel (BK; BKCa; Maxi-K; KCa1.1; Slo1))

Target
BK channel (BK; BKCa; Maxi-K; KCa1.1; Slo1)
Molecular classification
Ion channel, Voltage- and calcium-activated potassium channel (Kv family, KCa1.1), Pore-forming alpha subunit encoded by KCNMA1; assembles with auxiliary β1–β4 and γ1–γ4 subunits
01

Overview

The Large-conductance calcium-activated potassium channel is a tetrameric voltage- and Ca2+-activated K+ channel with exceptionally high single-channel conductance (~250–300 pS) that hyperpolarizes membranes by facilitating K+ efflux when activated by depolarization and/or elevated intracellular Ca2+. Its pore-forming alpha subunit is encoded by KCNMA1 (Slo1/KCa1.1) and contains seven transmembrane segments (S0–S6) with a voltage-sensor domain (S0–S4), a pore-gate domain (S5–S6), and a large cytosolic C-terminus with two RCK domains (RCK1/2) that harbor Ca2+ binding sites. Association with auxiliary β1–β4 and γ1–γ4 subunits diversifies gating kinetics, voltage/Ca2+ sensitivity, and pharmacology, enabling tissue-specific function. BK channels are widely expressed and key to limiting excitability by providing rapid negative feedback to Ca2+ influx, thereby regulating neuronal firing, neurotransmitter release, smooth muscle tone, circadian rhythms, hearing, renal and vascular physiology. Dysregulation or deficiency is linked to hypertension and neurodevelopmental disorders, and pharmacologic modulators include peptide blockers (e.g., iberiotoxin, with β4-dependent resistance) and small-molecule/openers (e.g., NS1619, BMS-191011) as well as steroidal enhancement in αβ complexes (17β-estradiol).

Other names
Big potassium channelMaxiKBKCaKCa1.1Slo1BK alpha subunitPotassium channel subfamily M alpha 1KCNMA1 channel
02

Mechanism of action

Blockers (e.g., iberiotoxin) bind the external pore and inhibit K+ efflux, increasing excitability; β4 subunit confers resistance to IbTX Activators/openers (e.g., NS1619, BMS-191011) increase BK open probability to enhance K+ efflux, promoting hyperpolarization and reduced Ca2+ entry Steroid modulation (17β-estradiol) enhances BK activity via αβ complexes, altering vascular and neuronal excitability Auxiliary subunit–dependent gating/inactivation: β2 subunit mediates ball-and-chain inactivation of human BK in the Ca2+-bound open state

03

Biological functions

Membrane repolarization and hyperpolarization after depolarization or Ca2+ riseRegulation of neuronal excitability and neurotransmitter releaseControl of smooth muscle tone and muscle contraction/relaxationFeedback regulation of voltage-gated Ca2+ channels and intracellular Ca2+ signalingContribution to circadian rhythms and hearing (hair cell tuning)Broad roles in cell excitability across neurons, muscle, kidney, vasculature
04

Disease associations

Cardiovascular disease (hypertension; vascular smooth muscle dysfunction)Neurological/neurodevelopmental disorders (epilepsy, autism, intellectual disability)Auditory dysfunction/hearing disordersRenal disease and fibrosis (preclinical evidence)Skeletal muscle channelopathies/periodic paralysis context and muscle atrophy modulation
05

Safety considerations

Ubiquitous expression and auxiliary subunit heterogeneity raise risks of off-target tissue effects (neuronal, vascular, renal)Excessive activation may cause hypotension, dizziness, or impaired neurotransmission; excessive blockade may provoke hypertension or seizures (risk inferred from physiological roles and disease links)Subunit-dependent pharmacology (e.g., β4-driven IbTX resistance) complicates predictability of drug effects across tissues
06

Interacting drugs

Channel blockers: iberiotoxin (selective scorpion peptide; reduced sensitivity with β4-containing BK)

3 more in the full profile.

07

Biomarkers

KCNMA1 gene expression or mutation status (BK channelopathy associations)Tissue-specific auxiliary subunit expression profiles (β1 in smooth muscle; β4 in brain; γ1 in secretory cells) to predict pharmacology (e.g., IbTX sensitivity) and response to modulatorsFunctional readouts: BK current density/conductance (~250–300 pS) and Ca2+/voltage sensitivity in target tissues

Beyond the preview

Go deeper on Large-conductance calcium-activated potassium channel (KCNMA1 alpha subunit) (BK channel (BK; BKCa; Maxi-K; KCa1.1; Slo1)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Large-conductance calcium-activated potassium channel (KCNMA1 alpha subunit) (BK channel (BK; BKCa; Maxi-K; KCa1.1; Slo1)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call